Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians

Angela Baralla, Elisabetta Sotgiu, Marta Deiana, Sara Pasella, Sara Pinna, Andrea Mannu, Elisabetta Canu, Giovanni Sotgiu, Antonello Ganau, Angelo Zinellu, Salvatore Sotgia, Ciriaco Carru, Luca Deiana, Angela Baralla, Elisabetta Sotgiu, Marta Deiana, Sara Pasella, Sara Pinna, Andrea Mannu, Elisabetta Canu, Giovanni Sotgiu, Antonello Ganau, Angelo Zinellu, Salvatore Sotgia, Ciriaco Carru, Luca Deiana

Abstract

The role of Clusterin in attenuation of inflammation and reverse cholesterol transfer makes this molecule a potential candidate as a marker for cancer, cardiovascular disease, diabetes mellitus, and metabolic syndrome. In elderly subjects cardiovascular diseases represent the primary cause of death and different clinical studies have shown a positive correlation of these diseases with changes in the lipid pattern. This work aimed at evaluating the relationship between circulating clusterin and the biochemical parameters that characterize the lipid profile of a Sardinian population divided into five age groups including centenarians; the high frequency in Sardinia of these long-lived individuals gave us the opportunity to extend the range of the age groups to be analyzed to older ages and to better evaluate the changes in the lipid balance during ageing and its relationship with clusterin concentration in plasma. Our results showed that Clusterin concentration values of the youngest group were more similar with the centenarian's group compared to the other age groups, and a positive correlation arises with LDL. Furthermore given the high prevalence of cardiovascular diseases in the population examined and the association of Clusterin with these pathologies we evaluated Clusterin concentration variation in two groups with or without cardiovascular diseases. In presence of cardiovascular disease, Clusterin is significantly related to the most atherogenic components of lipid profile (total cholesterol and LDL), especially in women, suggesting its potential role in modulating cardiovascular metabolic risk factors.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Lipid parameters’ values in the…
Fig 1. Lipid parameters’ values in the five age groups.
Boxplots represent the Lipid parameters analysed in the five age groups, total cholesterol, LDL (low density lipoprotein), HDL (high density lipoprotein) and Triglycerides. Circles represent outliers and asterix extreme outliers.
Fig 2. Clusterin concentration values in the…
Fig 2. Clusterin concentration values in the five age groups.
Boxplots represent the Clusterin concentration values in the five age groups. Circles represent outliers.

References

    1. Bettuzzi S (2009) Conclusions and perspectives. Adv Cancer Res 105: 133–150. 10.1016/S0065-230X(09)05008-8
    1. Blatter MC, James RW, Messmer S, Barja F, Pometta D (1993) Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 211: 871–879.
    1. Stuart WD, Krol B, Jenkins SH, Harmony JA (1992) Structure and stability of apolipoprotein J-containing high-density lipoproteins. Biochemistry 31: 8552–8559.
    1. Banfi C, Brioschi M, Barcella S, Wait R, Begum S, et al. (2009) Proteomic analysis of human low-density lipoprotein reveals the presence of prenylcysteine lyase, a hydrogen peroxide-generating enzyme. Proteomics 9: 1344–1352. 10.1002/pmic.200800566
    1. Karlsson H, Leanderson P, Tagesson C, Lindahl M (2005) Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5: 551–565.
    1. Sun HY, Chen SF, Lai MD, Chang TT, Chen TL, et al. (2010) Comparative proteomic profiling of plasma very-low-density and low-density lipoproteins. Clin Chim Acta 411: 336–344. 10.1016/j.cca.2009.11.023
    1. Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol 34: 427–431.
    1. Trougakos IP, Gonos ES (2002) Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34: 1430–1448.
    1. Choi-Miura NH, Oda T (1996) Relationship between multifunctional protein "clusterin" and Alzheimer disease. Neurobiol Aging 17: 717–722.
    1. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG (2004) Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23: 2298–2304.
    1. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, et al. (2000) Overexpression of clusterin in human breast carcinoma. Am J Pathol 157: 393–399.
    1. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, et al. (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13: 12–19.
    1. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, et al. (2008) A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14: 833–839. 10.1158/1078-0432.CCR-07-1310
    1. Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Corti A, et al. (2005) Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 12: 101–104.
    1. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278: 11590–11600.
    1. Zoubeidi A, Chi K, Gleave M (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16: 1088–1093. 10.1158/1078-0432.CCR-09-2917
    1. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR (1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274: 6875–6881.
    1. Michel D, Chatelain G, North S, Brun G (1997) Stress-induced transcription of the clusterin/apoJ gene. Biochem J 328 (Pt 1): 45–50.
    1. Wong P, Taillefer D, Lakins J, Pineault J, Chader G, et al. (1994) Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur J Biochem 221: 917–925.
    1. Ishikawa T, Zhu BL, Li DR, Zhao D, Michiue T, et al. (2006) Age-dependent increase of clusterin in the human pituitary gland. Leg Med (Tokyo) 8: 28–33.
    1. Lau KM, Tam NN, Thompson C, Cheng RY, Leung YK, et al. (2003) Age-associated changes in histology and gene-expression profile in the rat ventral prostate. Lab Invest 83: 743–757.
    1. Patel NV, Wei M, Wong A, Finch CE, Morgan TE (2004) Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neurosci Lett 371: 199–204.
    1. Trougakos IP, Gonos ES (2006) Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res 40: 1324–1334.
    1. Mackness B, Hunt R, Durrington PN, Mackness MI (1997) Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17: 1233–1238.
    1. Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, et al. (1998) Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 18: 665–672.
    1. Jordan-Starck TC, Lund SD, Witte DP, Aronow BJ, Ley CA, et al. (1994) Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J Lipid Res 35: 194–210.
    1. Gelissen IC, Hochgrebe T, Wilson MR, Easterbrook-Smith SB, Jessup W, et al. (1998) Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J 331 (Pt 1): 231–237.
    1. Schwarz M, Spath L, Lux CA, Paprotka K, Torzewski M, et al. (2008) Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb Haemost 100: 110–118. 10.1160/TH07-12-0737
    1. Martinez-Bujidos M, Rull A, Gonzalez-Cura B, Perez-Cuellar M, Montoliu-Gaya L, et al. (2014) Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. FASEB J.
    1. Won JC, Park CY, Oh SW, Lee ES, Youn BS, et al. (2014) Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS One 9: e103351 10.1371/journal.pone.0103351
    1. Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, et al. (2002) Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 37: 1175–1187.
    1. Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, et al. (2006) Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 13: 314–322.
    1. Poulakou MV, Paraskevas KI, Vlachos IS, Karabina SA, Wilson MR, et al. (2008) Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology 59: 137–144. 10.1177/0003319707311722
    1. Ishikawa Y, Ishii T, Akasaka Y, Masuda T, Strong JP, et al. (2001) Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis 158: 215–225.
    1. Deiana L, Ferrucci L, Pes GM, Carru C, Delitala G, et al. (1999) AKEntAnnos. The Sardinia Study of Extreme Longevity. Aging (Milano) 11: 142–149.
    1. Deiana L, Pes GM, Carru C, Ferrucci L, Franceschi C, et al. (2002) The "Oldest Man on the Planet". J Am Geriatr Soc 50: 2098–2099.
    1. Berns MA, de Vries JH, Katan MB (1988) Determinants of the increase of serum cholesterol with age: a longitudinal study. Int J Epidemiol 17: 789–796.
    1. Gillum RF, Taylor HL, Brozek J, Anderson J, Blackburn H (1982) Blood lipids in young men followed 32 years. J Chronic Dis 35: 635–641.
    1. Trougakos IP, Petropoulou C, Franceschi C, Gonos ES (2006) Reduced expression levels of the senescence biomarker clusterin/apolipoprotein j in lymphocytes from healthy centenarians. Ann N Y Acad Sci 1067: 294–300.
    1. Franceschi C, Bonafe M (2003) Centenarians as a model for healthy aging. Biochem Soc Trans 31: 457–461.
    1. Aronis KN, Vamvini MT, Chamberland JP, Mantzoros CS (2011) Circulating clusterin (apolipoprotein J) levels do not have any day/night variability and are positively associated with total and LDL cholesterol levels in young healthy individuals. J Clin Endocrinol Metab 96: E1871–1875. 10.1210/jc.2011-1555
    1. Miwa Y, Takiuchi S, Kamide K, Yoshii M, Horio T, et al. (2005) Insertion/deletion polymorphism in clusterin gene influences serum lipid levels and carotid intima-media thickness in hypertensive Japanese females. Biochem Biophys Res Commun 331: 1587–1593.
    1. Holliday R (1998) Causes of aging. Ann N Y Acad Sci 854: 61–71.
    1. Hui-Hui Liu J-JL (2014) Aging and dyslipidemia: A review of potential mechanisms. Aging Research Reviews 19: 43–52. 10.1016/j.arr.2014.12.001
    1. Gobal FA, Mehta JL (2010) Management of dyslipidemia in the elderly population. Ther Adv Cardiovasc Dis 4: 375–383. 10.1177/1753944710385048
    1. Kolovou G, Kolovou V, Vasiliadis I, Wierzbicki AS, Mikhailidis DP (2011) Ideal lipid profile and genes for an extended life span. Curr Opin Cardiol 26: 348–355. 10.1097/HCO.0b013e32834659d4
    1. Arai Y, Hirose N (2004) Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb 11: 246–252.
    1. Malaguarnera M, Giugno I, Ruello P, Rizzo M, Panebianco MP, et al. (1998) Lipid profile variations in a group of healthy elderly and centenarians. Eur Rev Med Pharmacol Sci 2: 75–79.
    1. Suzuki M, Wilcox BJ, Wilcox CD (2001) Implications from and for food cultures for cardiovascular disease: longevity. Asia Pac J Clin Nutr 10: 165–171.
    1. Walter M (2009) Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1244–1250. 10.1161/ATVBAHA.108.181438
    1. Baggio G, Donazzan S, Monti D, Mari D, Martini S, et al. (1998) Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 12: 433–437.
    1. Okamura T, Kadowaki T, Hayakawa T, Kita Y, Okayama A, et al. (2003) What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med 253: 169–180.
    1. Nago N, Ishikawa S, Goto T, Kayaba K (2011) Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol 21: 67–74.
    1. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). 2486–2497 p.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner